Steward Partners Investment Advisory LLC Acquires 330 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Steward Partners Investment Advisory LLC grew its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 4.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,050 shares of the biotechnology company’s stock after buying an additional 330 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Exelixis were worth $235,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Exelixis by 18.1% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 290 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its holdings in shares of Exelixis by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company’s stock valued at $1,937,000 after buying an additional 354 shares in the last quarter. Principal Securities Inc. boosted its holdings in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 373 shares in the last quarter. V Square Quantitative Management LLC boosted its holdings in shares of Exelixis by 37.3% during the 4th quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 425 shares in the last quarter. Finally, Fifth Third Bancorp boosted its stake in Exelixis by 16.1% in the 4th quarter. Fifth Third Bancorp now owns 3,231 shares of the biotechnology company’s stock worth $108,000 after purchasing an additional 449 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on EXEL shares. Stifel Nicolaus upped their price target on shares of Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research note on Wednesday, February 12th. Royal Bank of Canada upped their price target on shares of Exelixis from $38.00 to $40.00 and gave the stock an “outperform” rating in a research note on Thursday. Brookline Capital Management started coverage on shares of Exelixis in a research note on Monday, December 23rd. They issued a “buy” rating on the stock. Truist Financial upped their price target on shares of Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Finally, BMO Capital Markets cut shares of Exelixis from an “outperform” rating to a “market perform” rating and upped their price target for the stock from $36.00 to $40.00 in a research note on Friday, December 20th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.59.

Insider Activity

In other news, EVP Patrick J. Haley sold 52,636 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the sale, the executive vice president now owns 303,310 shares of the company’s stock, valued at $11,216,403.80. This represents a 14.79 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mary C. Beckerle sold 12,210 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the sale, the director now directly owns 30,406 shares of the company’s stock, valued at $1,060,561.28. The trade was a 28.65 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 140,343 shares of company stock valued at $5,177,234 in the last quarter. 2.85% of the stock is currently owned by insiders.

Exelixis Stock Down 0.4 %

NASDAQ EXEL opened at $36.65 on Friday. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $40.02. The firm has a market capitalization of $10.26 billion, a P/E ratio of 20.71, a PEG ratio of 1.13 and a beta of 0.57. The company has a 50-day moving average price of $35.36 and a 200-day moving average price of $32.43.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, equities research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.